Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy ...

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression of signals from nerves that promote bone marrow regeneration, according to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nineteen analysts that are covering the firm, Ratings reports. Eight research ...

A study published yesterday by the journal MedComm suggests that cannabidiol (CBD) may play a protective role in bone marrow recovery following acute radiation exposure. Bone marrow, home to ...

NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...